Antibiotic- and method-dependent variation in susceptibility testing results of Bacteroides fragilis group isolates.
The susceptibilities of 36 isolates of the Bacteroides fragilis group to ceftizoxime, cefoxitin, clindamycin, and metronidazole were determined by using the National Committee for Clinical Laboratory Standards agar dilution reference method and a broth microdilution method using anaerobe, brucella, Schaedler, and brain heart infusion broths. MICs that were greater than or equal to fourfold higher or lower than those of the reference method were considered significant. Major and minor discrepancies in susceptibility interpretation (SI) were also noted. Ceftizoxime showed the greatest number of variations and SI discrepancies. In 72% of the cases, MICs in broth were greater than or equal to fourfold lower than those obtained by the reference method, resulting in 33% of the major and 22% of the minor discrepancies in SI. A total of 53% of the isolates were resistant to ceftizoxime by the reference method, but only 11 to 17% were resistant in the various broths. Significant variations in MICs of cefoxitin occurred in 19 to 22% of the isolates; 17 to 19% of the isolates showed major discrepancies and 31 to 58% showed minor discrepancies in SI. A total of 58% of the isolates were resistant to cefoxitin by the reference method, but only 19 to 28% were resistant in the various broths. Significant variations with clindamycin in broths ranged from 32 to 53% and resulted in 3 to 8% of the isolates showing major discrepancies and 33 to 44% showing minor discrepancies in SI. Metronidazole yielded significant variations in MICs in 6 to 28% of the isolates, but no major or minor SI discrepancies were noted. This study indicates that significant differences in susceptibility results, which appear to be method related, can result when isolates of the B. fragilis group are tested. Therefore, studies correlating in vitro results, determined by various methods, to clinical outcome are essential.
D001439:Bacteroides / Q000187:drug effects; D001441:Bacteroides fragilis / Q000187:drug effects*; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology; D002440:Cefoxitin / Q000494:pharmacology; D015296:Ceftizoxime; D002511:Cephalosporins / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology*; D003470:Culture Media; D008795:Metronidazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests / Q000379:methods; D011786:Quality Control
D002511:Cephalosporins; D003470:Culture Media; D008795:Metronidazole; D002981:Clindamycin; D002440:Cefoxitin; D015296:Ceftizoxime; D002439:Cefotaxime